Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX48
- Development stage
- Phase 1
- Lead developer
- Henlius
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HLX48 is a bispecific antibody-drug conjugate (ADC) developed by Shanghai Henlius Biotech for the treatment of advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer. It simultaneously targets the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (c-MET). Developed using the proprietary Hanjugator™ ADC platform, HLX48 is designed to deliver a cytotoxic payload directly to tumor cells expressing these receptors, leveraging a bystander effect to enhance efficacy while maintaining a favorable safety profile. It is currently undergoing Phase I clinical evaluation to assess its safety, tolerability, and pharmacokinetics.
- Other names
- EGFR/c-MET Bispecific Antibody-Drug Conjugate
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on HLX48.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX48.